GlaxoSmithKline: Epilepsy trials

The registry lists 54 Epilepsy studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 23 have results posted.

Phase 1 12Phase 2 4Phase 3 18Phase 4 5No phase 15(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Valproate Dose Reduction and Its Clinical Evaluation by Introducing Lamotrigine in Japanese Women With Epilepsy - Single Arm, Multicenter, and Open-label StudyCompletedNCT02100644Phase 4Results posted
• A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset SeizuresCompletedNCT01777139Phase 3Results posted
• Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset SeizuresTerminatedNCT01721317Phase 4Results posted
• Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGSTerminatedNCT01668654Phase 3Results posted
• Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset SeizuresTerminatedNCT01648101Phase 3Results posted
• An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset SeizuresTerminatedNCT01607346Phase 4Results posted
• Study in Pediatric Subjects With EpilepsyTerminatedNCT01494584Phase 2Results posted
• Clinical Study of Lamotrigine to Treat Newly Diagnosed Typical Absence Seizure in Children and AdolescentsCompletedNCT01431976Phase 3Results posted
• Clinical Study of Lamotrigine to Treat Newly Diagnosed EpilepsyCompletedNCT01431963Phase 3Results posted
• Clinical and Economic Burden of Uncontrolled Epilepsy: Analyses From a Medicaid Database and a Private Health Plan DatabaseCompletedNCT01390909Results posted
• Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS)CompletedNCT01336621Phase 3Results posted
• Cancer in Patients With Gabapentin (GPRD)CompletedNCT01236053Results posted
• Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset SeizuresCompletedNCT01227902Phase 3Results posted
• Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)CompletedNCT01138124Results posted
• Lamotrigine Pregnancy Registry (LAM05)CompletedNCT01064297Results posted
• Lamotrigine Extended-Release In Elderly Patients With EpilepsyCompletedNCT00516139Phase 3Results posted
• Clinical Evaluation of BW430C in EpilepsyCompletedNCT00395694Phase 3Results posted
• Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial EpilepsyCompletedNCT00355082Phase 3Results posted
• Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial. 115097TerminatedNCT00310388Phase 3Results posted
• Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind TrialCompletedNCT00310375Phase 3Results posted
• Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in EpilepsyCompletedNCT00235755Phase 3Results posted
• Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in EpilepsyCompletedNCT00232596Phase 3Results posted
• Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Primary Generalized Tonic-Clonic Seizures (PGTC) SeizuresCompletedNCT00104416Phase 3Results posted
• The Bioequivalence Study of Lamotrigine Dispersible/Chewable Tablets 100mg Compared With Compressed Tablet 100 mgCompletedNCT02064465Phase 1
• REMS Retigabine StudyCompletedNCT01938560
• The Bioequivalence Study of Lamotrigine Dispersible/Chewable Tablets 5mg×5 Compared With Lamotrigine Compressed Tablet 25mg in Chinese Healthy Male SubjectsCompletedNCT01879423Phase 1
• Special Drug Use Investigation for LAMICTAL® (Long Term)CompletedNCT01863602
• Bioequivalence Study of 300 mg GabapentinCompletedNCT01738893Phase 1
• Trobalt™ Products Risk SurveyCompletedNCT01721213
• WEUSKOP6166: Lamotrigine and Aseptic MeningitisCompletedNCT01657864
• WEUKBRE5557: IMI PROTECT(Work Package 2): Antiepileptics & SuicideCompletedNCT01607333
• Systematic Review: Retigabine for Adjunctive Therapy in Partial EpilepsyCompletedNCT01587339
• An Open-label, Single-centre Study Evaluating the Pharmacokinetics of Digoxin Alone and When Administered at Various Doses of Ezogabine/Retigabine in Healthy Adults. The Pharmacokinetics of Ezogabine/Retigabine and the N-acetyl Metabolite of Ezogabine/Retigabine (NAMR) Will Also be AssessedCompletedNCT01583036Phase 1
• Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and Its N-acetyl MetaboliteCompletedNCT01480609Phase 1
• Crossover Study to Evaluate the Pharmacokinetics of Ezogabine/Retigabine in Taiwanese SubjectsCompletedNCT01462669Phase 1
• Risk of Urinary Retention With RetigabineTerminatedNCT01462656
• Meta-Analysis Plan for Pooled Data for Studies VRX-RET-E22-303 and VRX-RET-E22-304CompletedNCT01457989
• Drug Use Investigation for LAMICTALCompletedNCT01376180
• Lamotrigine Bioequivalence Study to Compare Dispersible Tables With Compressed Tablets in ChinaCompletedNCT01357902Phase 1
• An Open Label, Randomised, Repeat Dose Study to Assess the Pharmacokinetic Performance of Five Ezogabine/Retigabine Modified Release (MR) Formulations at Steady State Compared to the Immediate Release (IR) Formulation.CompletedNCT01332513Phase 1
• Birth Defects Associated With Exposure to Lamotrigine in Pregnancy (EUROCAT)CompletedNCT01055327
• AED/Statin Interaction StudyCompletedNCT00627575Phase 1
• Bioequivalence and Food Effect of 250mg of Lamotrigine XRCompletedNCT00605371Phase 1
• GW273225 Therapy Added To Current Seizure Treatments In Patients With Partial SeizuresWithdrawnNCT00567424Phase 2
• Bioequivalence And Lack Of Food Effects Of 300mg Lamotrigine XRCompletedNCT00412191Phase 1
• Spanish Validation Of Quality of Life Questionnaire (QOLIE-10) For EpilepsyCompletedNCT00264680
• Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended-Release Formulation And Vice VersaCompletedNCT00264615Phase 3
• LAMICTAL (Lamotrigine) For The Treatment Of Absence SeizuresCompletedNCT00144872Phase 1
• Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Partial SeizuresCompletedNCT00113165Phase 3
• Lethargic Depression StudyCompletedNCT00064467Phase 3
• Pediatric Epilepsy Study in Subjects 1-24 MonthsCompletedNCT00044278Phase 2
• Measurement Of Serum Levels Of Two Antiepileptic Drugs During Conversion In Patients With EpilepsyCompletedNCT00043914Phase 4
• Treatment Of Primary Generalized Tonic-Clonic Seizures With An Investigational New DrugCompletedNCT00043901Phase 4
• Pediatric Epilepsy Trial in Subjects 1-24 MonthsCompletedNCT00043875Phase 2